

**MTN 034 - Reversing the Epidemic in Africa with Choices in HIV Prevention (REACH)
Data as of December 4, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up by Site COVID-19^{1,2}

	SA Cape Town	SA Johannesburg	Uganda Kampala	Zimbabwe Spilhaus	All Sites
Participants Enrolled	60	67	60	60	247
1. ACASI Required and Expected	241	327	222	225	1015
Completed	208 (86.3%)	320 (97.9%)	216 (97.3%)	210 (93.3%)	954 (94.0%)
Not Completed	33 (13.7%)	7 (2.1%)	6 (2.7%)	15 (6.7%)	61 (6.0%)
2. Social Harms / Benefits Assessment Required and Expected	241	328	224	225	1018
Completed	239 (99.2%)	328 (100.0%)	224 (100.0%)	225 (100.0%)	1016 (99.8%)
Not Completed	2 (0.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (0.2%)
3. Physical Exam Required and Expected	694	907	610	615	2826
Completed	677 (97.6%)	896 (98.8%)	607 (99.5%)	615 (100.0%)	2795 (98.9%)
Not Completed	17 (2.4%)	11 (1.2%)	3 (0.5%)	0 (0.0%)	31 (1.1%)
4. Pelvic Exam Required and Expected	241	326	223	222	1012
Completed	204 (84.6%)	318 (97.5%)	219 (98.2%)	218 (98.2%)	959 (94.8%)
Not Completed	37 (15.4%)	8 (2.5%)	4 (1.8%)	4 (1.8%)	53 (5.2%)
5. Pregnancy Test Required and Expected	694	907	606	615	2822
Completed	679 (97.8%)	896 (98.8%)	593 (97.9%)	589 (95.8%)	2757 (97.7%)
Not Completed	15 (2.2%)	11 (1.2%)	13 (2.1%)	26 (4.2%)	65 (2.3%)
6. HIV-1 Test Required and Expected	685	903	610	612	2810
Completed	672 (98.1%)	889 (98.4%)	607 (99.5%)	611 (99.8%)	2779 (98.9%)
Not Completed	13 (1.9%)	14 (1.6%)	3 (0.5%)	1 (0.2%)	31 (1.1%)
7. HSV-2 Antibody Storage Required and Expected	55	67	54	56	232
Completed	53 (96.4%)	64 (95.5%)	54 (100.0%)	56 (100.0%)	227 (97.8%)
Not Completed	2 (3.6%)	3 (4.5%)	0 (0.0%)	0 (0.0%)	5 (2.2%)
8. Hepatitis B Surface Antigen Test Required and Expected	0	0	0	0	0
9. Blood Plasma Archive/Storage Required and Expected	241	328	224	225	1018
Completed	233 (96.7%)	320 (97.6%)	223 (99.6%)	225 (100.0%)	1001 (98.3%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit.

If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

² Only visits completed or expected to be completed on or after 26 March 2020 are included in this report.

**MTN 034 - Reversing the Epidemic in Africa with Choices in HIV Prevention (REACH)
Data as of December 4, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up by Site COVID-19^{1,2}

	SA Cape Town	SA Johannesburg	Uganda Kampala	Zimbabwe Spilhaus	All Sites
Not Completed	8 (3.3%)	8 (2.4%)	1 (0.4%)	0 (0.0%)	17 (1.7%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit.

If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

² Only visits completed or expected to be completed on or after 26 March 2020 are included in this report.

**MTN 034 - Reversing the Epidemic in Africa with Choices in HIV Prevention (REACH)
Data as of December 4, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up by Site COVID-19^{1,2}

	SA Cape Town	SA Johannesburg	Uganda Kampala	Zimbabwe Spilhaus	All Sites
10. Blood Chemistry Required and Expected	55	67	54	56	232
Completed	54 (98.2%)	64 (95.5%)	54 (100.0%)	56 (100.0%)	228 (98.3%)
Not Completed	1 (1.8%)	3 (4.5%)	0 (0.0%)	0 (0.0%)	4 (1.7%)
11. Hematology Required and Expected	55	67	54	56	232
Completed	54 (98.2%)	64 (95.5%)	54 (100.0%)	56 (100.0%)	228 (98.3%)
Not Completed	1 (1.8%)	3 (4.5%)	0 (0.0%)	0 (0.0%)	4 (1.7%)
12. Dried Blood Spot for PK Sample Storage Required and Expected (Truvada users only)	0	0	0	0	0
13. Rapid Test for Trichomonas Test Required and Expected	55	67	54	56	232
Completed	54 (98.2%)	67 (100.0%)	54 (100.0%)	56 (100.0%)	231 (99.6%)
Not Completed	1 (1.8%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
14. NAAT (Pelvic) for GC/CT Required and Expected	55	67	54	56	232
Completed	52 (94.5%)	62 (92.5%)	53 (98.1%)	56 (100.0%)	223 (96.1%)
Not Completed	3 (5.5%)	5 (7.5%)	1 (1.9%)	0 (0.0%)	9 (3.9%)
15. Vaginal PH Test Required and Expected	0	0	0	0	0
16. Vaginal Swabs for Microbiota	135	194	116	114	559
Completed	98 (72.6%)	189 (97.4%)	112 (96.6%)	107 (93.9%)	506 (90.5%)
Not Completed	37 (27.4%)	5 (2.6%)	4 (3.4%)	7 (6.1%)	53 (9.5%)
17. Vaginal Gram Stain Required and Expected	241	328	224	225	1018
Completed	201 (83.4%)	318 (97.0%)	219 (97.8%)	218 (96.9%)	956 (93.9%)
Not Completed	40 (16.6%)	10 (3.0%)	5 (2.2%)	7 (3.1%)	62 (6.1%)
18. Vaginal Swab for Biomarkers Required and Expected	241	328	224	225	1018
Completed	201 (83.4%)	316 (96.3%)	216 (96.4%)	209 (92.9%)	942 (92.5%)
Not Completed	40 (16.6%)	12 (3.7%)	8 (3.6%)	16 (7.1%)	76 (7.5%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit.

If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

² Only visits completed or expected to be completed on or after 26 March 2020 are included in this report.

**MTN 034 - Reversing the Epidemic in Africa with Choices in HIV Prevention (REACH)
Data as of December 4, 2022**

Visit Adherence: Completion of Procedures During Enrollment and Follow-up by Site COVID-19^{1,2}

	SA Cape Town	SA Johannesburg	Uganda Kampala	Zimbabwe Spilhaus	All Sites
19. CVL Supernatant for Biomarker Required and Expected	241	328	224	225	1018
Completed	201 (83.4%)	316 (96.3%)	216 (96.4%)	209 (92.9%)	942 (92.5%)
Not Completed	40 (16.6%)	12 (3.7%)	8 (3.6%)	16 (7.1%)	76 (7.5%)
20. CVL Pellet for Biomarker Required and Expected	241	328	224	225	1018
Completed	201 (83.4%)	316 (96.3%)	216 (96.4%)	209 (92.9%)	942 (92.5%)
Not Completed	40 (16.6%)	12 (3.7%)	8 (3.6%)	16 (7.1%)	76 (7.5%)
21. Cervical Swab for Biomarkers Required and Expected	241	328	224	225	1018
Completed	201 (83.4%)	316 (96.3%)	216 (96.4%)	209 (92.9%)	942 (92.5%)
Not Completed	40 (16.6%)	12 (3.7%)	8 (3.6%)	16 (7.1%)	76 (7.5%)
22. Cervical Cytobrush for Flow Cytometry Required and Expected (Zimbabwe only)	0	0	0	225	225
Completed	0 (-%)	0 (-%)	0 (-%)	212 (94.2%)	212 (94.2%)
Not Completed	0 (-%)	0 (-%)	0 (-%)	13 (5.8%)	13 (5.8%)

¹ Protocol-required follow-up visit procedures are expected only once the visit window has closed, and only for participants who attend the visit.

If a participant misses a visit, as documented by a Missed Visit eCRF, the procedures for that visit will not be included as expected.

² Only visits completed or expected to be completed on or after 26 March 2020 are included in this report.